SVRA Stock Analysis: Savara | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 1.037m USD | 12M Return: 34.4% | US8051111016 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 10.1M
Qual. Beats: -3
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Savara Inc. (NASDAQ: SVRA) is a clinical-stage biopharmaceutical company headquartered in Yardley, Pennsylvania, that develops therapies for rare respiratory diseases in the United States. Founded in 2007 and publicly listed since 2017, the companys lead asset is molgramostim, an inhaled formulation of granulocyte-macrophage colony-stimulating factor (GM-CSF) currently in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung disorder characterized by surfactant accumulation in the alveoli.
As a clinical-stage biotechnology company, Savara operates without approved commercial products, meaning its value is largely tied to the progression of its development pipeline rather than recurring revenue. Its focus on rare diseases positions it within a segment of the biopharmaceutical industry that often benefits from regulatory incentives such as orphan drug designation, which can include extended market exclusivity and accelerated review pathways.
- Molgramostim Phase 3 IMPALA-2 trial readout in aPAP
- FDA acceptance of BLA filing for molgramostim
- Cash runway extended through pivotal regulatory milestones
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.58 > 0.02 and ΔFCF/TA 2.29 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.57 > 3% & CFO -110.4m > Net Income -139.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 10.13 > 1.5 & < 3 |
| Outstanding Shares: last quarter (253.6m) vs 12m ago 17.16% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.17%; Δ -0.17% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.84 (Total Current Assets 178.3m - Total Current Liabilities 17.6m) / Total Assets 192.1m |
| B: -3.57 (Retained Earnings -685.6m / Total Assets 192.1m) |
| C: -0.78 (EBIT TTM -139.3m / Avg Total Assets 178.0m) |
| D: 2.96 (Book Value of Equity 143.7m / Total Liabilities 48.5m) |
| Altman-Z'' = -8.29 = D |
As of October 07, 2026, the stock is trading at USD 4.65 with a total of 2,291,156 shares traded. Over the past week, the price has changed by -8.46%, over one month by -15.91%, over three months by -25.00% and over the past year by +34.39%.
Current recommended Stop Loss: 4.30 (which is 7.5% or 1.5 ATR below the current price).
Savara has received a consensus analysts rating of 4.75. Therefore, it is recommended to buy SVRA.
- StrongBuy: 6
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 10.9 | 135.3% |
P/E Forward = 0.4076
P/S = 145272.6216
P/B = 7.1652
Revenue TTM = 0.0 USD
EBIT TTM = -139.3m USD
EBITDA TTM = -139.1m USD
Long Term Debt = 30.1m USD (from longTermDebt, last quarter)
Short Term Debt = 7.00k USD (from shortTermDebt, last fiscal year)
Debt = 30.4m USD (from shortLongTermDebtTotal, last quarter) + Leases 298k
Net Debt = -142.6m USD (calculated: Debt 30.4m - CCE 173.0m)
Enterprise Value = 893.9m USD (1.04b + Debt 30.4m - CCE 173.0m)
Interest Coverage Ratio = unknown (Ebit TTM -139.3m / Interest Expense TTM 0.0)
EV/FCF = -7.98x (Enterprise Value 893.9m / FCF TTM -112.0m)
FCF Yield = -12.53% (FCF TTM -112.0m / Enterprise Value 893.9m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 245k) / Revenue TTM)
Tobins Q-Ratio = 4.65 (Enterprise Value 893.9m / Total Assets 192.1m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 30.4m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -110.1m (EBIT -139.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.25 (Total Current Assets 178.3m / Total Current Liabilities 24.6m)
Debt / Equity = 0.21 (Debt 30.4m / totalStockholderEquity, last quarter 143.7m)
Debt / EBITDA = 1.03 (negative EBITDA) (Net Debt -142.6m / EBITDA -139.1m)
Debt / FCF = 1.27 (negative FCF - burning cash) (Net Debt -142.6m / FCF TTM -112.0m)
Total Stockholder Equity = 154.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -78.28% (Net Income -139.3m / Total Assets 192.1m)
RoE = -90.28% (Net Income TTM -139.3m / Total Stockholder Equity 154.3m)
RoCE = -75.54% (EBIT -139.3m / Capital Employed (Equity 154.3m + L.T.Debt 30.1m))
RoIC = -63.05% (negative operating profit) (NOPAT -110.1m / Invested Capital 174.5m)
WACC = 8.52% (E(1.04b)/V(1.07b) * Re(8.77%) + D(30.4m)/V(1.07b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 8.77% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 92.96 | Cagr: 15.73%
[DCF] Fair Price = unknown (Cash Flow -112.0m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -1.70 | # QB: -3
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.16 | Chg30d=-5.41% | Revisions=-38% | Analysts=5
EPS current Year (2026-12-31): EPS=-0.62 | Chg30d=-6.21% | Revisions=-38% | GrowthEPS=-16.2% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-0.31 | Chg30d=-6.12% | Revisions=-29% | GrowthEPS=+49.4% | GrowthRev=+3963.5%
[Analyst] Revisions Ratio: -47% (up=3, down=11)